Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Jarushka Naidoo, David B. Page, Bob T. Li, Louise C. Connell, Katja Schindler, Mario E. Lacouture, Michael A. Postow, Jedd D. Wolchok
Topics & Concepts
MedicineImmune checkpointMelanomaPD-L1BlockadeNivolumabClinical trialImmunotherapyAdverse effectAntibodyLung cancerCancerOncologyImmune systemImmunologyInternal medicineCancer researchReceptorCancer Immunotherapy and BiomarkersCAR-T cell therapy researchLung Cancer Treatments and Mutations